200 related articles for article (PubMed ID: 36153494)
1. Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer.
Jeon Y; Jo U; Hong J; Gong G; Lee HJ
BMC Cancer; 2022 Sep; 22(1):1014. PubMed ID: 36153494
[TBL] [Abstract][Full Text] [Related]
2. Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer.
Vidula N; Yau C; Rugo H
Breast Cancer Res Treat; 2022 Aug; 194(3):569-575. PubMed ID: 35789445
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
[TBL] [Abstract][Full Text] [Related]
5. TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer.
Cortesi M; Zanoni M; Maltoni R; Ravaioli S; Tumedei MM; Pirini F; Bravaccini S
Expert Opin Ther Targets; 2022 Jul; 26(7):593-602. PubMed ID: 35962580
[TBL] [Abstract][Full Text] [Related]
6. Comparative expression of trophoblast cell-surface antigen 2 (TROP2) in the different molecular subtypes of invasive breast carcinoma: An immunohistochemical study of 94 therapy-naive primary breast tumors.
Mertens RB; Makhoul EP; Li X; Dadmanesh F
Ann Diagn Pathol; 2024 Feb; 68():152226. PubMed ID: 37995412
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of TROP2 in human nasopharyngeal carcinoma.
Guan GF; Zhang DJ; Wen LJ; Yu DJ; Zhao Y; Zhu L; Guo YY; Zheng Y
Int J Clin Exp Pathol; 2015; 8(9):10995-1004. PubMed ID: 26617817
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway.
Liu T; Liu Y; Bao X; Tian J; Liu Y; Yang X
PLoS One; 2013; 8(9):e75864. PubMed ID: 24086649
[TBL] [Abstract][Full Text] [Related]
9. Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors.
Dum D; Taherpour N; Menz A; Höflmayer D; Völkel C; Hinsch A; Gorbokon N; Lennartz M; Hube-Magg C; Fraune C; Bernreuther C; Lebok P; Clauditz TS; Jacobsen F; Sauter G; Uhlig R; Wilczak W; Steurer S; Minner S; Marx AH; Simon R; Burandt E; Krech T; Luebke AM
Pathobiology; 2022; 89(4):245-258. PubMed ID: 35477165
[TBL] [Abstract][Full Text] [Related]
10. Could trop-2 overexpression indicate tumor aggressiveness among prostatic adenocarcinomas?
Akarken İ; Dere Y
Ann Diagn Pathol; 2021 Feb; 50():151680. PubMed ID: 33341704
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
12. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
Peng Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation.
Mito R; Matsubara E; Komohara Y; Shinchi Y; Sato K; Yoshii D; Ohnishi K; Fujiwara Y; Tomita Y; Ikeda K; Sakagami T; Suzuki M
Pathol Int; 2020 May; 70(5):287-294. PubMed ID: 32039532
[TBL] [Abstract][Full Text] [Related]
14. Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67.
Kashiwagi S; Yashiro M; Takashima T; Aomatsu N; Ikeda K; Ogawa Y; Ishikawa T; Hirakawa K
Breast Cancer Res; 2011; 13(6):R122. PubMed ID: 22126395
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer.
Liu H; Bai L; Huang L; Ning N; Li L; Li Y; Dong X; Du Q; Xia M; Chen Y; Zhao L; Li Y; Meng Q; Wang J; Duan Y; Ming J; Yuan AQ; Yang XP
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599021
[TBL] [Abstract][Full Text] [Related]
17. Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer.
Liu X; Deng J; Yuan Y; Chen W; Sun W; Wang Y; Huang H; Liang B; Ming T; Wen J; Huang B; Xing D
Pharmacol Ther; 2022 Nov; 239():108296. PubMed ID: 36208791
[TBL] [Abstract][Full Text] [Related]
18. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
19. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
[TBL] [Abstract][Full Text] [Related]
20. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy.
Son S; Shin S; Rao NV; Um W; Jeon J; Ko H; Deepagan VG; Kwon S; Lee JY; Park JH
Int J Biol Macromol; 2018 Apr; 110():406-415. PubMed ID: 29055700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]